Published in N Engl J Med on January 01, 2015
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA (2015) 6.38
Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA (2015) 5.45
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
Breast cancer risk by the extent and type of atypical hyperplasia. Cancer (2016) 1.08
Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer (2016) 1.02
Atypical hyperplasia of the breast. N Engl J Med (2015) 0.98
Atypical hyperplasia of the breast. N Engl J Med (2015) 0.96
Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. Ann Intern Med (2016) 0.92
Chemoprevention for Breast Cancer. Ann Surg Oncol (2015) 0.83
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol (2015) 0.81
Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. Breast (2015) 0.79
Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Med (2015) 0.78
Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer. Breast Cancer (Auckl) (2016) 0.77
Atypical hyperplasia of the breast. N Engl J Med (2015) 0.77
ERβ Expression and Breast Cancer Risk Prediction for Women with Atypias. Cancer Prev Res (Phila) (2015) 0.76
Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer (2015) 0.75
Quantitative diagnosis of breast tumors by morphometric classification of microenvironmental myoepithelial cells using a machine learning approach. Sci Rep (2017) 0.75
Novel role of cortactin in G protein-coupled receptor agonist-induced nuclear export and degradation of p21Cip1. Sci Rep (2016) 0.75
Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies. J Natl Cancer Inst (2017) 0.75
MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer? J Med Radiat Sci (2015) 0.75
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One (2015) 0.75
Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort. BMC Cancer (2017) 0.75
Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time? Ann Surg Oncol (2016) 0.75
How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention? NPJ Breast Cancer (2017) 0.75
Surgical implications and variability in the use of the flat epithelial atypia diagnosis on breast biopsy specimens. Breast (2017) 0.75
Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. JAMA Oncol (2017) 0.75
Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget (2017) 0.75
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A (2003) 6.35
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 6.14
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2013) 4.20
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer (1985) 3.92
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 3.83
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst (2011) 3.73
Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol (1992) 3.39
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 3.39
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
A prospective study of benign breast disease and the risk of breast cancer. JAMA (1992) 3.29
Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol (2010) 2.89
Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer (2001) 2.71
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med (1998) 2.38
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol (2012) 2.34
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol (2012) 2.11
Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet (2003) 2.08
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol (2001) 1.94
Breast cancer incidence in a cohort of women with benign breast disease from a multiethnic, primary health care population. Breast J (2007) 1.84
Benign breast disorders. N Engl J Med (2005) 1.80
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Breast cancer precursors revisited: molecular features and progression pathways. Histopathology (2010) 1.72
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat (2012) 1.66
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology (2010) 1.55
The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study. Cancer (2006) 1.44
Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol (2007) 1.31
Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med (2005) 1.28
Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol (2011) 1.28
Utilization of minimally invasive breast biopsy for the evaluation of suspicious breast lesions. Am J Surg (2011) 1.25
Is 'fibrocystic disease' of the breast precancerous? Arch Pathol Lab Med (1986) 1.23
Lobule type and subsequent breast cancer risk: results from the Nurses' Health Studies. Cancer (2009) 1.16
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol (2007) 1.15
Factors affecting breast cancer risk reduction practices among California physicians. Prev Med (2004) 1.14
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Long-term follow-up of lobular neoplasia (atypical lobular hyperplasia/lobular carcinoma in situ) diagnosed on core needle biopsy. Ann Surg Oncol (2012) 0.97
Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. Mod Pathol (2010) 0.97
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat (2012) 0.96
Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol (2001) 0.95
Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J (2009) 0.93
Atypical ductal hyperplasia on core biopsy: an automatic trigger for excisional biopsy? Ann Surg Oncol (2012) 0.91
Update on atypical epithelial hyperplasia and ductal carcinoma in situ. Pathology (2009) 0.91
Classic lobular carcinoma in situ and atypical lobular hyperplasia at percutaneous breast core biopsy: outcomes of prospective excision. Cancer (2012) 0.88
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) (2011) 0.88
Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy. Breast (2010) 0.83
Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction. Ann Surg Oncol (2011) 0.79
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Evidence of a causal role of winter virus infection during infancy in early childhood asthma. Am J Respir Crit Care Med (2008) 3.84
Effect of CPOE user interface design on user-initiated access to educational and patient information during clinical care. J Am Med Inform Assoc (2005) 2.85
Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 2.81
Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71
Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med (2002) 2.62
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
The impact of peer management on test-ordering behavior. Ann Intern Med (2004) 2.50
The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer (2005) 2.39
Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics (2008) 2.29
Influence of maternal asthma on the cause and severity of infant acute respiratory tract infections. J Allergy Clin Immunol (2012) 2.26
Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. Pediatrics (2007) 2.20
Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol (2002) 2.18
Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol (2012) 2.16
Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet (2003) 2.08
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
The severity-dependent relationship of infant bronchiolitis on the risk and morbidity of early childhood asthma. J Allergy Clin Immunol (2009) 1.91
Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2007) 1.90
The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A (2004) 1.89
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev (2007) 1.74
Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res (2007) 1.68
Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation (2009) 1.61
Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm (2012) 1.60
Quality of life after breast cancer surgery: What have we learned and where should we go next? J Surg Oncol (2009) 1.60
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol (2006) 1.55
The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest (2010) 1.55
Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol (2010) 1.50
Ethics and statistics in randomized clinical trials. Stat Sci (1991) 1.49
Estimating influenza hospitalizations among children. Emerg Infect Dis (2006) 1.41
Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology (2007) 1.39
Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program. Breast J (2014) 1.39
Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis. Steroids (2012) 1.38
Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer. Cancer Epidemiol Biomarkers Prev (2012) 1.37
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.32
Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology (2007) 1.32
Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab (2005) 1.29
Host and viral factors associated with severity of human rhinovirus-associated infant respiratory tract illness. J Allergy Clin Immunol (2011) 1.27
Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J Allergy Clin Immunol (2009) 1.26
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat (2009) 1.25
Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. J Allergy Clin Immunol (2007) 1.25
Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol (2009) 1.23
Increased hospital mortality in patients with bedside hippus. Am J Med (2008) 1.23
Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg (2008) 1.23
Current status of radioactive seed for localization of non palpable breast lesions. Am J Surg (2009) 1.21
Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol (2010) 1.21
Translating evidence-based information into effective risk communication: current challenges and opportunities. J Lab Clin Med (2005) 1.19
Membrane initiated estrogen signaling in breast cancer. Biol Reprod (2006) 1.16
Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer (2006) 1.16
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol (2010) 1.16
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem (2003) 1.15
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol (2007) 1.15
Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology (2002) 1.14
Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J (2013) 1.13
Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res (Phila) (2014) 1.13
Appendicitis after appendectomy. Arch Surg (2008) 1.13
Lobular involution: localized phenomenon or field effect? Breast Cancer Res Treat (2008) 1.12
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways. J Steroid Biochem Mol Biol (2003) 1.11
Quality-of-life impact of non-neoplastic voice disorders: a meta-analysis. Ann Otol Rhinol Laryngol (2006) 1.11
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg (2012) 1.10
Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. Ann Otol Rhinol Laryngol (2006) 1.09
Adenomyoepithelioma: clinical, histologic, and immunohistologic evaluation of a series of related lesions. Am J Surg Pathol (2005) 1.08
Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. Clin Sci (Lond) (2013) 1.08
Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol (2011) 1.07
Sclerotherapy for the treatment of postmastectomy seroma. Am J Surg (2008) 1.07
Breast manifestations of systemic diseases. Int J Womens Health (2012) 1.05
Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol (2009) 1.05
Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension (2007) 1.05
Dermatomyositis presenting as a paraneoplastic syndrome due to underlying breast cancer. BMJ Case Rep (2011) 1.05
Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.04
National practice patterns in preoperative and postoperative antibiotic prophylaxis in breast procedures requiring drains: survey of the American Society of Breast Surgeons. Ann Surg Oncol (2012) 1.04
Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol (2007) 1.04
Cost-effectiveness analysis of routine frozen-section analysis of breast margins compared with reoperation for positive margins. Ann Surg Oncol (2011) 1.03
Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer (2008) 1.03
Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat (2007) 1.03
Paget's disease of the breast: accuracy of preoperative assessment. Breast Cancer Res Treat (2006) 1.02
Abnormalities of angiotensin regulation in postural tachycardia syndrome. Heart Rhythm (2011) 1.02
Microbiology of surgical site infections complicating breast surgery. Surg Infect (Larchmt) (2010) 1.01
Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol (2004) 1.01
Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer (2006) 1.00
Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception. Eur J Pain (2009) 0.99
Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat (2014) 0.99
Pseudoangiomatous stromal hyperplasia and breast cancer risk. Ann Surg Oncol (2010) 0.98
Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol (2011) 0.98
Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer. Ann Surg Oncol (2010) 0.98
Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause (2008) 0.97
Incidence of clinically significant seroma after breast and axillary surgery. J Am Coll Surg (2008) 0.96
Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology (2010) 0.96
The diagnosis of endometrial carcinomas with clear cells by gynecologic pathologists: an assessment of interobserver variability and associated morphologic features. Am J Surg Pathol (2012) 0.96
Immunohistochemical expression of estrogen receptor in enlarged lobular units with columnar alteration in benign breast biopsies: a nested case-control study. Am J Surg Pathol (2005) 0.95